Osteopenia – Epidemiology – Epidemiology Dashboard
Clarivate’s Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of osteopenia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s Osteopenia will answer the following questions:
- Of all people with osteopenia, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with osteopenia, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of osteopenia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year,Clarivate Epidemiology also provides at least ten years of forecast data for the following osteopenia subpopulations:
- Total prevalent cases by diagnosis status.
- Diagnosed prevalent cases by drug treatment status.
Note: Coverage may vary by country.
